Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
Some people advocate giving Alzheimer's disease drugs to people with normal cognitive function who have elevated amyloid levels in their brains. This is not only wrong, but dangerous.| The Hastings Center